Journal
SCIENCE ADVANCES
Volume 8, Issue 12, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/sciadv.abg9055
Keywords
-
Categories
Funding
- INSERM, Paul Sabatier University
- Agence Nationale de la Recherche [ANR-17-CE14-0016]
- Association Francaise d'Etude et de Recherche sur l'Obesite
- Paul Sabatier University
- Region Midi-Pyrenees-INSERM [15050341]
- Region Occitanie, European funds (Fonds Europeens de Developpement Regional, FEDER), Toulouse Metropole
- French Ministry of Research
- Investissement d'Avenir Infrastructures Nationales en Biologie et Sante program (ProFI, Proteomics French Infrastructure project) [ANR-10-INBS-08]
- Region Occitanie
- Agence Nationale de la Recherche (ANR) [ANR-17-CE14-0016] Funding Source: Agence Nationale de la Recherche (ANR)
Ask authors/readers for more resources
Dysregulations of lipid metabolism in the liver may trigger steatosis progression, leading to potentially severe clinical consequences such as NAFLDs. Here, researchers identify the nuclear factor HMGB1 as a strong repressor of liver lipogenesis and suggest that targeting HMGB1 could be a new therapeutic option for NAFLD.
Dysregulations of lipid metabolism in the liver may trigger steatosis progression, leading to potentially severe clinical consequences such as nonalcoholic fatty liver diseases (NAFLDs). Molecular mechanisms underlying liver lipogenesis are very complex and fine-tuned by chromatin dynamics and multiple key transcription factors. Here, we demonstrate that the nuclear factor HMGB1 acts as a strong repressor of liver lipogenesis. Mice with liver-specific Hmgb1 deficiency display exacerbated liver steatosis, while Hmgb1-overexpressing mice exhibited a protection from fatty liver progression when subjected to nutritional stress. Global transcriptome and functional analysis revealed that the deletion of Hmgb1 gene enhances LXR. and PPAR. activity. HMGB1 repression is not mediated through nucleosome landscape reorganization but rather via a preferential DNA occupation in a region carrying genes regulated by LXR. and PPAR.. Together, these findings suggest that hepatocellular HMGB1 protects from liver steatosis development. HMGB1 may constitute a new attractive option to therapeutically target the LXR.-PPAR. axis during NAFLD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available